Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Shionogi Influenza Campaign Causes Stir among Healthcare Professionals
January 29, 2014
- Lurasidone Receives CHMP Positive Opinion: DSP, Takeda
January 29, 2014
- Kenko.com Sues Government over Restriction of Online OTC Drug Sales
January 28, 2014
- Asano Named as New Asahi Kasei President
January 28, 2014
- Zydus to Withdraw from Japan, Discontinuing Shipments by March-End Due to Policy Change of Parent Company
January 28, 2014
- Ajinomoto to Downsize In-House Drug Discovery Research amid Slack Pharma Biz
January 27, 2014
- BioWa Out-Licenses Kyowa Hakko Kirin’s Technologies and Serves as Its “In-Licensing Window”; “Naked” Mabs to Remain Dominant until 2002
January 27, 2014
- Sanwa Kagaku, Dong-A ST of South Korea Sign License Deal for Nesp Biosimilar in Japan
January 27, 2014
- Novartis Used Interim Report of “Sign” Trial in Tasigna Promotion, Set to Probe Its Involvement in Protocol Drafting
January 24, 2014
- Antidepressant Brintellix Launched in US: Takeda, Lundbeck
January 24, 2014
- Novartis Adds LABA/LAMA Combination Ultibro to Lineup of Breezhaler Products for COPD Using the Same Inhaler
January 24, 2014
- Novartis Pharma Involvement Suspected in Drafting of Sign Trial Protocol
January 23, 2014
- Azilva Remains No.1 in December “Mind Share” Ranking in GP, HP Markets
January 22, 2014
- Japan’s 1st Sublingual Immunotherapy Wins Approval: Torii
January 21, 2014
- Sales Reps Vied over Questionnaire Transfers in Tasigna Trial, Boss OK’ed Incentive Program: Novartis
January 21, 2014
- NBI Receives Approval for Giotrif, Sets to Enter Oncology Field
January 21, 2014
- Nissan Chemical Sues Nichi-Iko, Two Other Companies over Livalo Patent
January 21, 2014
- Novartis Sales Reps Transferred Patient Questionnaires in Investigator-Led Trial
January 20, 2014
- Japan’s First SGLT-2 Inhibitor Suglat Approved: Astellas
January 20, 2014
- Otsuka Files Abilify Once-Monthly Injectable in Japan
January 17, 2014
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…